Cargando…

Genetics of Keratoconus: Where Do We Stand?

Keratoconus is a progressive thinning and anterior protrusion of the cornea that results in steepening and distortion of the cornea, altered refractive powers, and reduced vision. Keratoconus has a complex multifactorial etiology, with environmental, behavioral, and multiple genetic components contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abu-Amero, Khaled K., Al-Muammar, Abdulrahman M., Kondkar, Altaf A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164130/ https://www.ncbi.nlm.nih.gov/pubmed/25254113 http://dx.doi.org/10.1155/2014/641708

Ejemplares similares

Keratoconus is associated with increased copy number of mitochondrial DNA
por: Abu-Amero, Khaled. K., et al.
Publicado: (2014)

Analysis of the VSX1 gene in keratoconus patients from Saudi Arabia
por: Abu-Amero, Khaled K., et al.
Publicado: (2011)

Genetics in Keratoconus: where are we?
por: Bykhovskaya, Yelena, et al.
Publicado: (2016)

An Updated Review on the Genetics of Primary Open Angle Glaucoma
por: Abu-Amero, Khaled, et al.
Publicado: (2015)

High-resolution analysis of DNA copy number alterations in patients with isolated sporadic keratoconus
por: Abu-Amero, Khaled K., et al.
Publicado: (2011)

Utility of Circulating MicroRNAs as Clinical Biomarkers for Cardiovascular Diseases
por: Kondkar, Altaf A., et al.
Publicado: (2015)

Barrett's Esophagus: Where Do We Stand?
por: Al Madi, Majid A.
Publicado: (2009)

Screening of the Seed Region of MIR184 in Keratoconus Patients from Saudi Arabia
por: Abu-Amero, Khaled K., et al.
Publicado: (2015)

Polymorphism rs13334190 in zinc finger protein 469 (ZNF469) is not a risk factor for keratoconus in a Saudi cohort
por: Kalantan, Hatem, et al.
Publicado: (2017)

Case-control association between CCT-associated variants and keratoconus in a Saudi Arabian population
por: Abu-Amero, Khaled K., et al.
Publicado: (2015)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

Resveratrol and Ophthalmic Diseases
por: Abu-Amero, Khaled K., et al.
Publicado: (2016)

Where Do We Stand?
Publicado: (1891)

Maximizing neuroprotection: where do we stand?
por: Kuffler, Damien P
Publicado: (2012)

Where do we stand with IPF treatment?
por: Albera, C, et al.
Publicado: (2013)

Schistosomiasis vaccines: where do we stand?
por: Tebeje, Biniam Mathewos, et al.
Publicado: (2016)

Vaccine for Diabetes—Where Do We Stand?
por: Chellappan, Dinesh Kumar, et al.
Publicado: (2022)

Telemedicine in India: Where do we stand?
por: Chellaiyan, Vinoth G., et al.
Publicado: (2019)

Cricoid pressure: Where do we stand?
por: Bhatia, Nidhi, et al.
Publicado: (2014)

Bevacizumab in Glaucoma: Where do We Stand?
por: Khanna, Anjani
Publicado: (2012)

The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
por: Werner, Rudolf A., et al.
Publicado: (2018)

COVID-19 and AKI: Where Do We Stand?
por: Palevsky, Paul M.
Publicado: (2021)

The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?
por: Agapidou, Alexandra, et al.
Publicado: (2016)

Late Sodium Current of the Heart: Where Do We Stand and Where Are We Going?
por: Horváth, Balázs, et al.
Publicado: (2022)

Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
por: Eichenauer, Dennis A., et al.
Publicado: (2023)

Nature and nurture in neuropsychiatric genetics: where do we stand?
por: Dick, Danielle M., et al.
Publicado: (2010)

Enigma of Extrapulmonary Tuberculosis: Where Do We Stand?
por: Inayat, Faisal, et al.
Publicado: (2017)

Genetic Predisposition and Inflammatory Inhibitors in COVID-19: Where Do We Stand?
por: Sagris, Marios, et al.
Publicado: (2022)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Biliary atresia: Where do we stand now?
por: Govindarajan, Krishna Kumar
Publicado: (2016)

Current Melanoma Treatments: Where Do We Stand?
por: Moreira, Alvaro, et al.
Publicado: (2021)

Neurogenic Erectile Dysfunction. Where Do We Stand?
por: Thomas, Charalampos, et al.
Publicado: (2021)

Tumor-Associated Microbiome: Where Do We Stand?
por: Oliva, Marc, et al.
Publicado: (2021)

Targeting Apoptosis in AML: Where Do We Stand?
por: Krawiec, Kinga, et al.
Publicado: (2022)

Nanocarriers for Skin Applications: Where Do We Stand?
por: Tiwari, Neha, et al.
Publicado: (2021)

Selenium, Stroke, and Infection: A Threefold Relationship; Where Do We Stand and Where Do We Go?
por: Liampas, Andreas, et al.
Publicado: (2023)

Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?
por: Radzina, Maija, et al.
Publicado: (2023)

Sirtuins Expression and Their Role in Retinal Diseases
por: Balaiya, Sankarathi, et al.
Publicado: (2017)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?
por: Banz-Jansen, Constanze, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7du13ncgs1g43vhdrqdr4obu8e